ABC-06 vertical bar A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy
Authors
Lamarca, AngelaPalmer, DH
Wasan, HS
Ross, PJ
Ma, YT
Arora, A
Falk, S
Gillmore, R
Wadsley, J
Patel, K
Anthoney, A
Maraveyas, A
Waters, JS
Hobbs, C
Barber, S
Ryder, D
Ramage, J
Davies, LM
Bridgewater, JA
Valle, Juan W
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust / Institute of Cancer Sciences, University of Manchester, ManchesterIssue Date
2019
Metadata
Show full item recordCitation
Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol. 2019;37(15_suppl):4003-.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.15_suppl.4003Additional Links
https://dx.doi.org/10.1200/JCO.2019.37.15_suppl.4003Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.15_suppl.4003